<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718482</url>
  </required_header>
  <id_info>
    <org_study_id>OsteoREC2015</org_study_id>
    <nct_id>NCT02718482</nct_id>
  </id_info>
  <brief_title>Phase II Trial for the Treatment of Relapsed Osteosarcoma</brief_title>
  <acronym>OsteoREC2015</acronym>
  <official_title>Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the
      Ifosfamide treatment of patients with relapsed osteosarcoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with relapsed osteosarcoma will be randomized to receive Gemcitabine plus Docetaxel
      or High Doses Ifosfamide (continuous infusion) every 3 weeks, up to 6 weeks
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not adequate enrollment (sample size not possible to reach)
  </why_stopped>
  <start_date type="Actual">April 6, 2016</start_date>
  <completion_date type="Actual">January 7, 2019</completion_date>
  <primary_completion_date type="Actual">January 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>at 6 months from randomization</time_frame>
    <description>Survival without progression of disease assessed at 6 months from randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>After 6, 12 and 18 weeks</time_frame>
    <description>Rate of tumor response assessed after cycle 2, 4 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At patient death or at last available follow-up</time_frame>
    <description>From date of starting therapy until the date of death from any cause, whichever came first, assessed up to 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post treatment Surgery Rate</measure>
    <time_frame>After 6, 12 and 18 weeks</time_frame>
    <description>Rate of patients who will require surgery after 2, 4 and 6 study treatment cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Incidence</measure>
    <time_frame>Every 3 weeks up to 22 weeks</time_frame>
    <description>Number and grade of adverse events related to the study treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assesment: data will be collected by using specific oncologic Quality of Life instruments</measure>
    <time_frame>After 6, 12 and 18 weeks and at 12 Months after end of treatment</time_frame>
    <description>Quality of Life evaluation related to received chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>After 1,3, 4, 6, 7, 9, 10, 12, 13, 15, 16 and 18 weeks</time_frame>
    <description>Number of days spent in hospital related to treatment received</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>OSTEOSARCOMA</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ifosfamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Docetaxel</intervention_name>
    <description>Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle</description>
    <arm_group_label>Gemcitabine and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle</description>
    <arm_group_label>Ifosfamide</arm_group_label>
    <other_name>High doses ifosfamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of high grade osteosarcoma recurrence

          -  Resectable or unresectable recurrence disease within 24 months from the initial
             diagnosis

          -  Pleuro-pulmonary recurrence with more than 2 nodules within 24 months from the initial
             diagnosis

          -  Unresectable first relapse within 24 months from the initial diagnosis

          -  Resectable or unresectable second of further recurrence of high grade osteosarcoma

          -  Age at diagnosis at least 4years.

          -  Karnofsky performance status over 60%.

          -  Renal function and hepatic In normal limits for age.

          -  L eft ejection ventricular fraction over 50%.

          -  White blood cells over 3000 million/liter and platelets 100000 million/liter

          -  Birth potential female must agreed to contraception

          -  Signed written informed consent

        Exclusion Criteria:

          -  Contraindication to the use of any study drugs

          -  Mental, social and geographic conditions which fail to ensure adequate adherence to
             the study

          -  Hepatitis and human immunodeficiency virus active infection

          -  Pregnancy or breast-feeding

          -  Previous treatment with Gemcitabine, Docetaxel and Ifosfamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Gradenigo</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università seconda di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena - IFO</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995 Mar 1;75(5):1084-93.</citation>
    <PMID>7850705</PMID>
  </reference>
  <reference>
    <citation>Bacci G, Briccoli A, Ferrari S, Ruggieri P, Avella M, Casadei R, Battistini A, Picci P. [Osteosarcoma of the extremities metastatic at presentation. Results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesion]. Minerva Chir. 1993 Jan;48(1-2):35-45. Italian.</citation>
    <PMID>8464555</PMID>
  </reference>
  <reference>
    <citation>Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002 Feb 1;20(3):776-90.</citation>
    <PMID>11821461</PMID>
  </reference>
  <reference>
    <citation>Meazza C, Casanova M, Luksch R, Podda M, Favini F, Cefalo G, Massimino M, Ferrari A. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer. 2010 Oct;55(4):617-20. doi: 10.1002/pbc.22596.</citation>
    <PMID>20589638</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

